Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3
Science Advances · 25.07.2025 · 11 (30)
DOI: 10.1126/sciadv.adv4238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 25.07.2025. Verfasst von Caifeng Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Interleukin-1beta, Sirtuin 3. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osteoarthritis (OA) is a multifactorial disease characterized by joint inflammation and cartilage degeneration, with no disease-modifying drugs available. The vicious cycle between the inflammatory microenvironment (inflamed soil) and dysfunctional chondrocytes (degeneration-related seeds) drives the chronic progressive deterioration of OA. Here, we report a genetically engineered chondrocyte-mimetic nanoplatform (termed HKL-GECM@MPNPs) comprising a honokiol (HKL)–loaded mitochondrion-targeting nanoparticle core coated with an interleukin-1 receptor type 2 (IL-1R2)–overexpressing chondrocyte membrane. HKL-GECM@MPNPs fuse with OA chondrocytes, transferring IL-1R2 onto the plasma membrane and reprogramming the inflamed microenvironment through IL-1β blockade. Mitochondrion-targeting cores then directly deliver HKL to restore mitochondrial sirtuin-3 in OA chondrocytes, reprogramming the cells’ pathological phenotype. Intra-articular injection of HKL-GECM@MPNPs in OA mice reduces inflammation, alleviates joint pain, and mitigates cartilage damage through a synergistic effect. Moreover, HKL-GECM@MPNPs effectively reverse cartilage degeneration in human OA cartilage explants. This approach highlights the potential of HKL-GECM@MPNPs to combine IL-1β blockade and mitochondrial sirtuin-3 restoration as a promising strategy for OA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
- Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China.
- Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University, Changsha, China.
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, Singapore.
- Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore.
- Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Caifeng Deng, Liukang Yu, Jie Wei, Xiaoyuan Chen, Guanghua Lei, Chao Zeng
Zitieren
APA
Deng, C., Yu, L., Zhao, X., Chen, Y., Mei, J., Wei, J., Chen, X., Lei, G., & Zeng, C. (2025). Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3. Science Advances, 11(30). https://doi.org/10.1126/sciadv.adv4238
Vancouver
Deng C, Yu L, Zhao X, Chen Y, Mei J, Wei J, et al. Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3. Science Advances. 2025;11(30). doi:10.1126/sciadv.adv4238
BibTeX
@article{Deng2025,
author = {Deng, Caifeng and Yu, Liukang and Zhao, Xuan and Chen, Yuxiao and Mei, Jiabin and Wei, Jie and Chen, Xiaoyuan and Lei, Guanghua and Zeng, Chao},
title = {Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {30},
doi = {10.1126/sciadv.adv4238}
}
EUVIMED